Morgan Stanley raises Chime Financial price target on bank acquisition

Morgan Stanley raised Chime Financial's price target to $40 from $39 and retained its Overweight rating after Chime agreed to acquire Stride Bank for $590 million, with closing expected in early 2027. The national bank charter is expected to broaden Chime's lending reach beyond the roughly 85% of members accessible through its sponsor-bank model and support longer-duration credit products. Chime shares trade at $32.31, up 43% over six months and 28% year-to-date; the company remains unprofitable on an LTM basis but reported an 89% gross margin and a 4.6 current ratio.

Analysis

The strategic value is not the charter itself but the ability to convert a large transaction-account base into higher-yielding revolving and installment credit without third-party-bank product constraints. That should lift revenue per active member and reduce partner-bank economics over a 6-18 month horizon, but it also moves CHYM from a largely fee/interchange-driven model toward direct exposure to unsecured-credit losses, CECL reserve volatility, funding costs, and bank-capital requirements. The relevant valuation question is therefore whether incremental credit contribution exceeds the higher capital intensity and loss provisioning—not whether gross margin remains high.

The delayed closing creates an unusual catalyst gap: investors may capitalize product optionality now while the balance-sheet consequences arrive only after regulatory approval and integration. A national-bank acquisition can attract heightened scrutiny around consumer compliance, CRA obligations, AML controls, and the operational separation of insured deposits from any digital-asset offering; any conditions imposed by regulators could materially reduce the expected speed-to-market benefit. The announced stablecoin exploration is strategically lower-value than the credit opportunity and may instead raise compliance expense and headline risk.

Competitive pressure should increase for SOFI and NU, which already market broader credit ecosystems and can frame themselves as more mature full-stack financial institutions. Conversely, CHYM's member-retention upside is most credible if it demonstrates that higher-income cohorts adopt credit products without a corresponding deterioration in delinquency; this is a cohort-quality thesis, not simply a distribution thesis. Consensus appears to be treating the transaction as immediately accretive to growth, while underestimating the potential for dilution from cash deployment, required capital at the bank subsidiary, and elevated loss reserves in the first full underwriting cycles.

Key Decisions for Investors

• Do not chase CHYM on analyst-target momentum. Establish a 1-3 month watch position only if management discloses expected capital contributions, pro forma CET1/liquidity requirements, and unit economics for the new revolving product; absent those disclosures, the upside case cannot be distinguished from multiple expansion.
• For a 6-18 month relative-value expression, consider long CHYM / short SOFI in equal beta-adjusted dollars only after regulatory approval is progressing on schedule. CHYM has greater untapped member monetization, while SOFI has more mature credit exposure; exit if CHYM's early-vintage delinquencies exceed management's underwriting targets or deal conditions require material incremental capital.
• Use SOFI as the cleaner alternative for investors seeking immediate bank-model exposure: it has already absorbed the transition to direct lending and deposit funding. This is preferable to a standalone CHYM long until the acquisition's timing, regulatory conditions, and credit-loss assumptions are quantified.
• Set a downside alert around any guidance showing rising provision expense faster than credit revenue, or an announced closing delay beyond early 2027. Either would challenge the thesis that charter ownership produces rapid operating leverage and could trigger a meaningful de-rating of CHYM's growth multiple.